This retrospective cohort study assessed the cardiovascular safety of phentermine (PHEN) and topiramate (TPM), both individually and in combination, including the fixed-dose formulation (PHEN/TPM), in adults aged ≥18 years using U.S. insurance claims data from the MarketScan database. The primary outcome was the incidence of major adverse cardiovascular events (MACE),
